Verve Therapeutics Inc (NASDAQ: VERV) on Friday, soared 5.43% from the previous trading day, before settling in for the closing price of $4.60. Within the past 52 weeks, VERV’s price has moved between $4.30 and $19.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 126.44% over the last five years. The company achieved an average annual earnings per share of 21.22%. With a float of $63.09 million, this company’s outstanding shares have now reached $81.97 million.
The firm has a total of 255 workers. Let’s measure their productivity. In terms of profitability, gross margin is 73.07%, operating margin of -928.6%, and the pretax margin is -806.35%.
Verve Therapeutics Inc (VERV) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Verve Therapeutics Inc is 25.48%, while institutional ownership is 76.15%. The most recent insider transaction that took place on May 14 ’24, was worth 475,760. In this transaction an insider of this company bought 76,000 shares at a rate of $6.26, taking the stock ownership to the 342,509 shares. Before that another transaction happened on Apr 02 ’24, when Company’s Chief Administrative Officer sold 1,514 for $8.24, making the entire transaction worth $12,475. This insider now owns 8,659 shares in total.
Verve Therapeutics Inc (VERV) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 21.22% per share during the next fiscal year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Verve Therapeutics Inc (VERV) is currently performing well based on its current performance indicators. A quick ratio of 13.05 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.79 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Analysing the last 5-days average volume posted by the [Verve Therapeutics Inc, VERV], we can find that recorded value of 1.88 million was better than the volume posted last year of 1.34 million. As of the previous 9 days, the stock’s Stochastic %D was 9.44%. Additionally, its Average True Range was 0.43.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 14.91%, which indicates a significant decrease from 17.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.40% in the past 14 days, which was higher than the 78.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.35, while its 200-day Moving Average is $7.28. Now, the first resistance to watch is $4.98. This is followed by the second major resistance level at $5.10. The third major resistance level sits at $5.34. If the price goes on to break the first support level at $4.61, it is likely to go to the next support level at $4.37. Should the price break the second support level, the third support level stands at $4.25.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
Market capitalization of the company is 432.94 million based on 84,664K outstanding shares. Right now, sales total 11,760 K and income totals -200,070 K. The company made 6,870 K in profit during its latest quarter, and -50,130 K in sales during its previous quarter.
